@article {7965,
	title = {Rituximab therapy in monoclonal IgM-related neuropathies},
	journal = {Leukemia and Lymphoma},
	volume = {47},
	year = {2006},
	note = {Cited By :34Export Date: 21 February 2017},
	month = {2006},
	pages = {859 - 864},
	abstract = {Monoclonal IgM-related neuropathies constitute a heterogeneous group of disorders, which are generally poorly responsive to treatment. Rituximab, a chimeric monoclonal antibody against the CD20 molecule, has been used with success in patients with neuropathy and monoclonal IgM with anti-MAG or anti-GM1 ganglioside activity. Based on this observation, four patients were treated with IgM-related neuropathy with rituximab. Between January 1999 - December 2000, four patients with IgM-related neuropathy (one with chronic inflammatory demyelinating polyneuropathy (CIDP) and three with sensorimotor demyelinating neuropathy) were treated with rituximab. Rituximab was administered at a standard dose of 375 mg m-2 iv weekly for a consecutive 4 weeks; 3 months later, four additional weekly courses were administered to patients who did not experience deterioration of their neuropathy symptoms. Neurological evaluation was performed before each rituximab infusion and at 1 week and 2 months after last infusion and every 6 months the following years; including motor (MRC in six muscle groups, 9-hole peg test, 10m walk, hand grip strength), sensory neuropathy (vibration threshold and sensory subjective score) assessment. Neurophysiological parameters were also assessed (MNCV, SNCV, CMAP, SNAP). Strength improved in three of four patients; including the patient with CIDP. This patient developed a significant worsening of her weakness 3 weeks after the initiation of rituximab. This phenomenon coincided with a serum monoclonal IgM flare and resolved spontaneously 1 week later. Her improvement is ongoing for more than 5 years. Considering neurophysiological parameters, two patients showed a slight improved regarding conduction velocities and CMAP (10\%) and the patient with IgM flare had a transient worsening of conduction velocities followed by improvement. In conclusion, rituximab is a safe and well-tolerated treatment which may be effective in some patients with IgM-related neuropathy. {\textcopyright} 2006 Taylor \&amp; Francis.},
	keywords = {CIDP, IgM-related neuropathy, rituximab},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-33744921114\&doi=10.1080\%2f14786410500441664\&partnerID=40\&md5=2b35af027f69cfb8d938b88d5f41e302},
	author = {Kilidireas, C. and Anagnostopoulos, A. and Karandreas, N. and Mouselimi, L. and Dimopoulos, M.-A.}
}
